NTC 801

Drug Profile

NTC 801

Alternative Names: BMS-914392; BMS-914392-01; NTC-801; NTC-801F

Latest Information Update: 19 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nissan Chemical Industries
  • Developer Nissan Chemical Industries; Teijin Pharma
  • Class Antiarrhythmics
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Atrial fibrillation; Atrial flutter

Most Recent Events

  • 04 Jun 2015 Suspended - Phase-II for Atrial fibrillation in Japan (PO) before June 2015
  • 04 Jun 2015 Suspended - Phase-II for Atrial flutter in Japan (PO) before June 2015
  • 10 Mar 2009 Bristol-Myers Squibb enters into a collaboration with Nissan Chemical Industries and Teijin Pharma for development and commercialisation of NTC 801 worldwide, except Japan, for Atrial fibrillation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top